Axa S.A. Lineage Cell Therapeutics, Inc. Transaction History

Axa S.A.

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q4 2019 Feb 18, 2020	SELL	$0.54 - $1.01 $632,618 - $1.18 Million	-1,171,515 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$0.85 - $1.24 $995,787 - $1.45 Million	1,171,515 New	1,171,515 $1.15 Million

121

94.2M

63.8K

Ticker LCTX
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 169,755,008
Market Cap $102M
Description
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...

Get notified when there are updates to the investment portfolio of Axa S.A., based on Form 13F filings with the SEC.

Stay updated on Axa S.A. with notifications on news.